Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 23742252)

1.

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY.

J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26.

PMID:
23742252
2.

LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor.

Chen J, Jiang C, Wang S.

J Med Chem. 2013 Jul 25;56(14):5673-4. doi: 10.1021/jm401005u. Epub 2013 Jul 9. No abstract available.

PMID:
23837797
3.

CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Cristofani F, Machiorlatti R, Abele C, Ator MA, Dorsey BD, Inghirami G, Ruggeri BA.

Mol Cancer Ther. 2012 Mar;11(3):670-9. doi: 10.1158/1535-7163.MCT-11-0776. Epub 2011 Dec 27.

4.

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.

Gingrich DE, Lisko JG, Curry MA, Cheng M, Quail M, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Haltiwanger RC, Wells-Knecht K, Ott GR, Ghose AK, Ator MA, Ruggeri B, Dorsey BD.

J Med Chem. 2012 May 24;55(10):4580-93. doi: 10.1021/jm201550q. Epub 2012 May 7.

PMID:
22564207
5.

Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment.

Park CH, Choe H, Jang IY, Kwon SY, Latif M, Lee HK, Lee HJ, Yang EH, Yun JI, Chae CH, Cho SY, Choi SU, Ha JD, Jung H, Kim HR, Kim P, Lee CO, Yun CS, Lee K.

Bioorg Med Chem Lett. 2013 Nov 15;23(22):6192-6. doi: 10.1016/j.bmcl.2013.08.090. Epub 2013 Sep 4.

PMID:
24095090
7.

Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy.

Kawakita Y, Miwa K, Seto M, Banno H, Ohta Y, Tamura T, Yusa T, Miki H, Kamiguchi H, Ikeda Y, Tanaka T, Kamiyama K, Ishikawa T.

Bioorg Med Chem. 2012 Oct 15;20(20):6171-80. doi: 10.1016/j.bmc.2012.08.002. Epub 2012 Aug 25.

PMID:
22980219
8.

Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.

Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, Christensen JG, Smith BJ, Shetty B.

J Pharmacol Exp Ther. 2012 Mar;340(3):549-57. doi: 10.1124/jpet.111.188870. Epub 2011 Nov 30.

9.

Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

Mesaros EF, Burke JP, Parrish JD, Dugan BJ, Anzalone AV, Angeles TS, Albom MS, Aimone LD, Quail MR, Wan W, Lu L, Huang Z, Ator MA, Ruggeri BA, Cheng M, Ott GR, Dorsey BD.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):463-6. doi: 10.1016/j.bmcl.2010.10.115. Epub 2010 Oct 27. Erratum in: Bioorg Med Chem Lett. 2011 Mar 15;21(6):1900.

PMID:
21074994
10.

Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway.

Ioannidis S, Lamb ML, Wang T, Almeida L, Block MH, Davies AM, Peng B, Su M, Zhang HJ, Hoffmann E, Rivard C, Green I, Howard T, Pollard H, Read J, Alimzhanov M, Bebernitz G, Bell K, Ye M, Huszar D, Zinda M.

J Med Chem. 2011 Jan 13;54(1):262-76. doi: 10.1021/jm1011319. Epub 2010 Dec 7.

PMID:
21138246
11.

Impact of hydrolysis-mediated clearance on the pharmacokinetics of novel anaplastic lymphoma kinase inhibitors.

Teffera Y, Berry LM, Brake RL, Lewis RT, Saffran DC, Moore E, Liu J, Zhao Z.

Drug Metab Dispos. 2013 Jan;41(1):238-47. doi: 10.1124/dmd.112.047993. Epub 2012 Nov 1.

12.

A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors.

Rodrigues FS, Yang X, Nikaido M, Liu Q, Kelsh RN.

ACS Chem Biol. 2012 Dec 21;7(12):1968-74. doi: 10.1021/cb300361a. Epub 2012 Sep 24.

PMID:
22985331
13.

Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.

Salphati L, Pang J, Plise EG, Lee LB, Olivero AG, Prior WW, Sampath D, Wong S, Zhang X.

Drug Metab Dispos. 2012 Sep;40(9):1785-96. doi: 10.1124/dmd.112.046052. Epub 2012 Jun 13.

14.

Targeted Therapy for Neuroblastoma: ALK Inhibitors.

Schulte JH, Schulte S, Heukamp LC, Astrahantseff K, Stephan H, Fischer M, Schramm A, Eggert A.

Klin Padiatr. 2013 Nov;225(6):303-8. doi: 10.1055/s-0033-1357132. Epub 2013 Oct 28. Review.

PMID:
24166094
15.

Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.

af Gennäs GB, Mologni L, Ahmed S, Rajaratnam M, Marin O, Lindholm N, Viltadi M, Gambacorti-Passerini C, Scapozza L, Yli-Kauhaluoma J.

ChemMedChem. 2011 Sep 5;6(9):1680-92. doi: 10.1002/cmdc.201100168. Epub 2011 Jun 30.

PMID:
21721129
16.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
17.

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H, Epstein LF, Emkey R, Andrews PS, Yu VL, Saffran DC, Xu M, Drew A, Merkel P, Szilvassy S, Brake RL.

J Med Chem. 2012 Jul 26;55(14):6523-40. doi: 10.1021/jm3005866. Epub 2012 Jul 10.

PMID:
22734674
18.

Inhibitors of the anaplastic lymphoma kinase.

Mologni L.

Expert Opin Investig Drugs. 2012 Jul;21(7):985-94. doi: 10.1517/13543784.2012.690031. Epub 2012 May 22. Review.

PMID:
22612599
19.

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.

Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SN, Reiter A, Siebert R, Melnick A, Woessmann W.

PLoS One. 2011 Apr 8;6(4):e18436. doi: 10.1371/journal.pone.0018436.

20.

The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.

Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, Hollenbach SJ, Pandey A, Sinha U.

J Pharmacol Exp Ther. 2014 Dec;351(3):538-48. doi: 10.1124/jpet.114.218164. Epub 2014 Sep 24.

PMID:
25253883
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk